Determination — Prescription of pharmaceutical benefits by authorised optometrists
(PB 11 of 2009)
as amended
made under subsections 85A (1) and (2) and 88(1C) of the
National Health Act 1953
This compilation was prepared on 1 November 2010
taking into account amendments up to PB 98 of 2010
Prepared by the Office of Legislative Drafting and Publishing,
Attorney‑General’s Department, Canberra
Determination — Prescription of pharmaceutical benefits by authorised
optometrists (PB 11 of 2009)
1 Commencement [see Note 1]
This instrument commences on 1 March 2009.
2 Repeal
Instrument number PB 116 of 2008 is repealed.
3 Definition
In this instrument:
Act means the National Health Act 1953.
4 Form allowable
For subsection 85A(1) of the Act, the form of a pharmaceutical benefit mentioned in an item of Schedule 1 that is allowable for prescription by an authorised optometrist is the form mentioned in the description of the pharmaceutical benefit in the item.
Note More than 1 form may have been determined for a pharmaceutical benefit , in which case each form is allowable for prescription: see Acts Interpretation Act 1901, para 23 (b).
5 Maximum quantity or number of units
(1) For paragraph 85A (2) (a) of the Act, the maximum quantity or number of units of a pharmaceutical benefit mentioned in an item of Schedule 1 that an authorised optometrist may, in 1 prescription, direct to be supplied on any 1 occasion, either for all purposes or for a particular purpose (if any) mentioned in the item, is the quantity or number of units mentioned in the item.
(2) For this section, the maximum quantity of a pharmaceutical benefit mentioned in an item in Schedule 1 is in the form mentioned in the description of the pharmaceutical benefit in the item.
Note A pharmaceutical benefit may or may not have a pharmaceutical item. The description of a pharmaceutical benefit in an individual item of Schedule 1 makes it clear whether the item relates to a pharmaceutical benefit that has a pharmaceutical item or not.
6 Maximum number of repeats
For paragraph 85A (2) (b) of the Act, the maximum number of occasions for which an authorised optometrist may, in 1 prescription, direct that the supply of a pharmaceutical benefit mentioned in an item of Schedule 1 be repeated, either for all purposes or for a particular purpose (if any) mentioned in the item, is the number mentioned in the item.
7 Manner of administration
For paragraph 85A (2) (c) of the Act, the manner of administration of a pharmaceutical benefit mentioned in an item of Schedule 1 that an authorised optometrist may, in a prescription, direct to be used is the manner of administration mentioned in the description of the pharmaceutical benefit in the item.
8 Pharmaceutical benefits that may be prescribed by authorised optometrists
For subsection 88 (1C) of the Act, an authorised optometrist is authorised to write a prescription for the supply of a pharmaceutical benefit that is mentioned in Schedule 1.
9 Particular purpose of supply of a pharmaceutical benefit
For sections 4 and 5, if there are any particular purposes for which the supply of a pharmaceutical benefit may be directed:
(a) those purposes are identified by the purpose code in the item of Schedule 1 dealing with the particular pharmaceutical benefit; and
(b) the purpose that the purpose code stands for is set out in the lower part of the item.
SCHEDULE 1 MATTERS RELATING TO THE WRITING OF PRESCRIPTIONS FOR PHARMACEUTICAL BENEFITS BY (sections 3 to 7) | |||||||
Pharmaceutical Benefit | Purposes of Supply | ||||||
Listed drug | Form | Manner of administration | Brand | For all purposes (other than a particular purpose) | For particular purposes (purpose code followed by quantity or number) | ||
Maximum quantity or number | Maximum repeats | Maximum quantity or number | Maximum repeats | ||||
Aciclovir | Eye ointment 30 mg per g, 4.5 g | Application to the eye | Zovirax | 1 | .. |
|
|
Betaxolol | Eye drops, suspension, 2.5 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Betoptic S | 1 | 5 |
|
|
| Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Betoptic BetoQuin | 1 | 5 |
|
|
Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | Lumigan | 1 | 5 |
|
|
Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) | Application to the eye | Ganfort 0.3/5 | 1 | 5 |
|
|
Brimonidine | Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL | Application to the eye | Alphagan P 1.5 | 1 | 5 |
|
|
| Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | Application to the eye | Alphagan Enidin | 1 | 5 |
|
|
Brimonidine with Timolol | Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg | Application to the eye | Combigan | 1 | 5 |
|
|
Brinzolamide | Eye drops 10 mg per mL, 5 mL | Application to the eye | Azopt BrinzoQuin | 1 | 5 |
|
|
Brinzolamide with Timolol | Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Azarga | 1 | 5 |
|
|
Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye | GelTears PAA Viscotears | 1 | 5 |
|
|
| Eye gel 2 mg per g, single dose units 0.6 mL, 30 | Application to the eye | Viscotears | 3 | 5 |
|
|
Carbomer 974 | Ocular lubricating gel 3 mg per g, single dose units 0.5 g, 30 | Application to the eye | Poly Gel | 3 | 5 |
|
|
Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the eye | Refresh Tears Plus | 1 | 5 |
|
|
| Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the eye | Refresh Liquigel | 1 | 5 |
|
|
| Eye drops containing carmellose sodium 2.5 mg per mL, single dose units 0.6 mL, 24 | Application to the eye | TheraTears | 4 | 5 |
|
|
| Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Cellufresh | 3 | 5 |
|
|
SCHEDULE 1 MATTERS RELATING TO THE WRITING OF PRESCRIPTIONS FOR PHARMACEUTICAL BENEFITS BY (sections 3 to 7) | |||||||
Pharmaceutical Benefit | Purposes of Supply | ||||||
Listed drug | Form | Manner of administration | Brand | For all purposes (other than a particular purpose) | For particular purposes (purpose code followed by quantity or number) | ||
Maximum quantity or number | Maximum repeats | Maximum quantity or number | Maximum repeats | ||||
| Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Celluvisc | 3 | 5 |
|
|
| Ocular lubricating gel containing carmellose sodium 10 mg per mL, single dose units 0.6 mL, 28 | Application to the eye | TheraTears | 3 | 5 |
|
|
Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, | Application to the eye | Optive | 1 | 3 |
|
|
| Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Optive | 3 | 5 |
|
|
Chloramphenicol | Eye drops 5 mg per mL, 10 mL | Application to the eye | Chloromycetin Chlorsig | 1 | 2 |
|
|
| Eye ointment 10 mg per g, 4 g | Application to the eye | Chloromycetin Chlorsig | 1 | .. |
|
|
Cromoglycic Acid | Eye drops containing sodium cromoglycate 20 mg per mL, 10 mL | Application to the eye | Cromolux Opticrom | 1 | 5 |
|
|
Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Trusopt | 1 | 5 |
|
|
Dorzolamide with Timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol | Application to the eye | Cosopt | 1 | 5 |
|
|
Fluorometholone | Eye drops 1 mg per mL, 5 mL | Application to the eye | Flucon FML Liquifilm | 1 | .. |
|
|
| Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL | Application to the eye | Flarex | 1 | .. |
|
|
Flurbiprofen | Eye drops containing flurbiprofen sodium 300 micrograms per mL, single dose units 0.4 mL, 5 | Application to the eye | Ocufen | 1 | .. |
|
|
Framycetin | Eye or ear drops containing framycetin sulfate 5 mg per mL, 8 mL | Application to the eye/ear | Soframycin | 1 | 2 |
|
|
Hydrocortisone | Eye ointment containing hydrocortisone acetate 5 mg per g, 5 g | Application to the eye | Hycor | 1 | .. |
|
|
| Eye ointment containing hydrocortisone acetate 10 mg per g, 5 g | Application to the eye | Hycor | 1 | .. |
|
|
Hypromellose | Eye drops 3 mg per mL, 15 mL | Application to the eye | Genteal In a Wink Moisturising | 1 | 5 |
|
|
| Eye drops 5 mg per mL, 15 mL | Application to the eye | Methopt | 1 | 5 |
|
|
Hypromellose with Carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the eye | Genteal gel HPMC PAA | 1 | 5 |
|
|
Hypromellose with Dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | Application to the eye | Poly-Tears Tears Naturale | 1 | 5 |
|
|
| Eye drops containing 3 mg hypromellose 2900 with 1 mg dextran 70 per mL, single dose units 0.4 mL, 28 | Application to the eye | Bion Tears | 3 | 5 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | Xalatan | 1 | 5 |
|
|
Latanoprost with Timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Xalacom | 1 | 5 |
|
|
Paraffin | Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Duratears Poly Visc | 2 | 5 |
|
|
| Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Ircal Lacri-Lube Poly Visc | 1 | 5 |
|
|
Pilocarpine | Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL | Application to the eye | Isopto Carpine | 1 | 5 |
|
|
| Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL | Application to the eye | Isopto Carpine | 1 | 5 |
|
|
| Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL | Application to the eye | Isopto Carpine | 1 | 5 |
|
|
Polyethylene glycol 400 | Eye drops 2.5 mg per mL, 15 mL | Application to the eye | Blink Intensive Tears | 1 | 5 |
|
|
| Eye drops 2.5 mg per mL, single dose units 0.4 mL, 20 | Application to the eye | Blink Intensive Tears | 5 | 5 |
|
|
Polyethylene Glycol 400 with Propylene Glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the eye | Systane | 1 | 5 |
|
|
| Eye drops 4 mg-3 mg per mL, single dose units 0.8 mL, 28 | Application to the eye | Systane | 2 | 5 |
|
|
Polyvinyl Alcohol | Eye drops 14 mg per mL, 15 mL | Application to the eye | Liquifilm Tears PVA Tears | 1 | 5 |
|
|
| Eye drops 14 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) | Application to the eye | Vistil | 1 | 5 |
|
|
| Eye drops 30 mg per mL, 15 mL | Application to the eye | Liquifilm Forte PVA Forte | 1 | 5 |
|
|
| Eye drops 30 mg per mL, 15 mL (contains sodium chlorite/hydrogen peroxide as preservative) | Application to the eye | Vistil Forte | 1 | 5 |
|
|
Soy lecithin | Eye spray 10 mg per mL, 10 mL | Application | tearsagain | 2 | 5 |
|
|
Sulfacetamide | Eye drops containing sulfacetamide sodium 100 mg per mL, 15 mL | Application to the eye | Bleph 10 | 1 | 2 |
|
|
Timolol | Eye drops 2.5 mg (as maleate) per mL, 5 mL | Application to the eye | Tenopt Timoptol | 1 | 5 |
|
|
| Eye drops 5 mg (as maleate) per mL, 5 mL | Application to the eye | Tenopt Timoptol | 1 | 5 |
|
|
| Eye drops (gellan gum solution) 2.5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Timoptol XE | 1 | 5 |
|
|
| Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Timoptol XE | 1 | 5 |
|
|
| Eye gel 1 mg (as maleate) per g, 5 g | Application to the eye | Nyogel | 1 | 5 |
|
|
Travoprost | Eye drops 40 micrograms per mL, 2.5 mL | Application to the eye | Travatan | 1 | 5 |
|
|
Travoprost with Timolol | Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Duotrav | 1 | 5 |
|
|
Notes to the Determination — Prescription of pharmaceutical benefits by authorised optometrists
(PB 11 of 2009)
Note 1
The Determination — Prescription of pharmaceutical benefits by authorised optometrists (PB 11 of 2009) (in force under subsections 85A(1) and (2) and 88(1C) of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.
Table of Instruments
Title | Date of FRLI Registration | Date of | Application, saving or |
PB 11 of 2009 | 12 Feb 2009 (see F2009L00427) | 1 Mar 2009 |
|
PB 27 of 2009 | 20 Mar 2009 (see F2009L01118) | 1 Apr 2009 | — |
PB 52 of 2009 | 11 June 2009 (see F2009L02292) | 1 July 2009 | — |
PB 67 of 2009 | 10 July 2009 (see F2009L02716) | 1 Aug 2009 | — |
PB 111 of 2009 | 20 Nov 2009 (see F2009L04285) | 1 Dec 2009 | — |
PB 19 of 2010 | 17 Mar 2010 (see F2010L00677) | 1 Apr 2010 | — |
PB 37 of 2010 | 15 Apr 2010 (see F2010L00939) | 1 May 2010 | — |
PB 71 of 2010 | 16 July 2010 (see F2010L02064) | 1 Aug 2010 | — |
PB 98 of 2010 | 29 Oct 2010 (see F2010L02857) | 1 Nov 2010 | — |
Table of Amendments
ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted | |
Provision affected | How affected |
Schedule 1 |
|
Schedule 1................. | am. PB 27, 52, 67 and 111 of 2009; PB 19, 37, 71 and 98 of 2010 |